Iboflaxacin

Ibafloxacin is a quinolone antibiotic drug used in veterinary medicine approved by international non-proprietary name (INN).

Ibaflin is indicated for the treatment of the following conditions in dogs:

Dermal infections (pyoderma – superficial and deep, wounds, abscesses) caused by susceptible strains

Of Staphylococci, E. coli, and Proteus mirabilis.

Acute, uncomplicated urinary tract infections, caused by susceptible strains of Staphylococci, Proteus

spp., Enterobacter spp., E. coli and Klebsiella spp.

Respiratory tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and

Klebsiella spp.

Do not use in dogs during the period of growth as articular cartilage may be affected. This period depends on the breed. For the majority of breeds the use of Ibafloxacin is contra-indicated in dogs less than 8 months of age and in giant breeds less than 18 months. Do not use in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with a

history of seizures.

Persons with known hypersensitivity to quinolone should avoid any contact with the product. The influence on fertility in male breeding dogs has not been studied. Heavy reliance on a single class of antibiotic may result in the induction of resistance in a bacterial Population. It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions which

have responded poorly, or are expected to respond poorly, to other classes of antibiotic. Ibaflin should

only be used based on susceptibility testing.

Do not use in dogs with known quinolone hypersensitivity.

Pyoderma is mostly secondary to an underlying disease. It is advisable to determine the underlying cause

and to treat the animal accordingly.

Antacids can interfere with gastro-intestinal absorption of quinolone. Antagonism may be observed with

Nitrofurantoin.

The safety of the veterinary medicinal product has not been established during lactation. Ibaflin can be

used during pregnancy